This disclosure relates to compounds that act as activators of the NRF2/KEAP1/ARE pathway. Such compounds are useful in the treatment of a variety of diseases including Huntingtons disease, Parkinsons disease, Alzheimers disease, inflammation, and cancer.La présente invention concerne des composés qui servent dactivateurs de la voie NRF2/KEAP1/ARE. De tels composés sont utiles dans le traitement de diverses maladies comprenant la maladie de Huntington, la maladie de Parkinson, la maladie dAlzheimer, linflammation, et le cancer.